These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF; Green TD; Ross TM Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849 [TBL] [Abstract][Full Text] [Related]
7. Vaccine to prevent AIDS overstated. Lewis D Res Initiat Treat Action; 1999 Jan; 5(1):11-2. PubMed ID: 11366223 [TBL] [Abstract][Full Text] [Related]
8. The RV144 Thai HIV vaccine trial. Plotkin SA Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337 [No Abstract] [Full Text] [Related]
9. Prime-boost immunization strategies against HIV. Barnett SW; Klinger JM; Doe B; Walker CM; Hansen L; Duliège AM; Sinangil FM AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S299-309. PubMed ID: 9814958 [No Abstract] [Full Text] [Related]
10. Immunologic mechanism for human immunodeficiency virus type 1 gp120 vaccine failure. O'Toole C; Müller S; Nara P; Köhler H J Infect Dis; 1996 Feb; 173(2):512-3. PubMed ID: 8568327 [No Abstract] [Full Text] [Related]
12. In search of a human immunodeficiency virus vaccine. Bartholomew CF West Indian Med J; 2000 Sep; 49(3):187-9. PubMed ID: 11076204 [No Abstract] [Full Text] [Related]
13. Antibodies to HIV-1: aiming at the right target. Eggink D; Melchers M; Sanders RW Trends Microbiol; 2007 Jul; 15(7):291-4. PubMed ID: 17566740 [TBL] [Abstract][Full Text] [Related]
14. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391 [TBL] [Abstract][Full Text] [Related]
15. An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. Song XT; Evel-Kabler K; Rollins L; Aldrich M; Gao F; Huang XF; Chen SY PLoS Med; 2006 Jan; 3(1):e11. PubMed ID: 16381597 [TBL] [Abstract][Full Text] [Related]
16. CD4-induced epitopes in the HIV envelope glycoprotein, gp120. DeVico AL Curr HIV Res; 2007 Nov; 5(6):561-71. PubMed ID: 18045112 [TBL] [Abstract][Full Text] [Related]
17. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576 [No Abstract] [Full Text] [Related]
18. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. Kawamura M; Wang X; Uto T; Sato K; Ueno M; Akagi T; Hiraishi K; Matsuyama T; Akashi M; Baba M J Med Virol; 2005 May; 76(1):7-15. PubMed ID: 15778965 [TBL] [Abstract][Full Text] [Related]
19. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals. Wrin T; Nunberg JH AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602 [No Abstract] [Full Text] [Related]
20. RV144: old vs. new. Weiner DB Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335 [No Abstract] [Full Text] [Related] [Next] [New Search]